By Arthi Shridhar
To keep up with demand, manufacturers face the difficult task of shortening the timeline between discovery and clinical implementation. The speed at which these therapies are developing and the corresponding cycle time for manufacture raises a host of supply chain struggles, beginning with the need to acquire stable and high-quality raw materials. To complicate the matter further, companies face labor challenges and the need for temperature-controlled distribution to ensure that final products are delivered in a safe and efficacious condition. What challenges do outdated cryopreservation techniques add for companies attempting to meet the growing demand for CGT therapies?